Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease
- PMID: 25755422
- PMCID: PMC3940561
- DOI: 10.1016/S0973-6883(12)60102-9
Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease
Abstract
Non-alcoholic fatty liver disease (NAFLD) is an important cause of liver disease burden across the world. By definition, although the histopathologic features of NAFLD are identical to that of alcoholic liver disease, its diagnosis requires absence of significant alcohol use and absence of other causes of chronic liver disease. We now know that NAFLD is not simply a disease of the Western world. It is manifested across the world, in varying rates, across gender, across varying ethnicities, and in its association with other host factors. In this review article, the definition of NAFLD, its spectrum, ranging from mild steatosis to hepatocellular injury and inflammation defined as non-alcoholic steatohepatitis (NASH) is discussed. Mild steatosis is generally a stable disease whereas NASH can be progressive. Based on current published literature, current incidence and prevalence of NAFLD and NASH are discussed. It is also accepted that these processes will continue to increase in prevalence with the rise of obesity, type II diabetes, and associated metabolic syndrome. Some of the risk factors have been well-established and are discussed. In addition, this review also presents emerging associations with other risk factors for NAFLD. Natural history of NAFLD is variable depending upon the histologic subtypes and other underlying comorbidities and is discussed in this review as well.
Keywords: CVD, cardiovascular disease; HCC, hepatocellular carcinoma; NAFLD; NAFLD, non-alcoholic fatty liver disease; NASH; NASH, non-alcoholic steatohepatitis; NHANES, National Health and Nutrition Examination Surveys; OSA, obstructive sleep apnea; PCOS, polycystic ovarian syndrome.
Similar articles
-
Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.Indian J Med Res. 2019 Jan;149(1):9-17. doi: 10.4103/ijmr.IJMR_1456_17. Indian J Med Res. 2019. PMID: 31115369 Free PMC article. Review.
-
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4. Metabolism. 2017. PMID: 28521870 Review.
-
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8. J Hepatol. 2018. PMID: 29886156
-
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263. World J Gastroenterol. 2017. PMID: 29307986 Free PMC article. Review.
-
Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges.Hepatol Res. 2015 Jan;45(1):20-8. doi: 10.1111/hepr.12333. Epub 2014 May 20. Hepatol Res. 2015. PMID: 24661406
Cited by
-
The Association Between Different Obesity Phenotypes and Liver Fibrosis Scores in Elderly Individuals with Fatty Liver in Taiwan.Diabetes Metab Syndr Obes. 2021 Mar 30;14:1473-1483. doi: 10.2147/DMSO.S302207. eCollection 2021. Diabetes Metab Syndr Obes. 2021. PMID: 33833538 Free PMC article.
-
Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.J Endocrinol Invest. 2017 Dec;40(12):1279-1288. doi: 10.1007/s40618-017-0708-9. Epub 2017 Jun 13. J Endocrinol Invest. 2017. PMID: 28612285
-
Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease.BMJ Open Gastroenterol. 2016 Aug 16;3(1):e000106. doi: 10.1136/bmjgast-2016-000106. eCollection 2016. BMJ Open Gastroenterol. 2016. PMID: 27648297 Free PMC article.
-
Alcoholic vs. Nonalcoholic Steatohepatitis: Vascular Branching Heterogeneity on Magnetic Resonance Imaging as a Diagnostic Marker.J Clin Transl Hepatol. 2023 Jun 28;11(3):534-539. doi: 10.14218/JCTH.2022.00279. Epub 2023 Jan 10. J Clin Transl Hepatol. 2023. PMID: 36969887 Free PMC article.
-
Cherry Anthocyanins Regulate NAFLD by Promoting Autophagy Pathway.Oxid Med Cell Longev. 2019 Feb 25;2019:4825949. doi: 10.1155/2019/4825949. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 30931080 Free PMC article.
References
-
- Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. Asia-Pacific Working Party on NAFLD. J Gastroenterol Hepatol. 2007;22:778. - PubMed
-
- Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474. - PubMed
-
- American Gastroenterological Association (AGA) medical position Statement Non-alcoholic fatty liver disease. Gastroenterology. 2002;123:1702–1704. - PubMed
-
- Suzuki A, Angulo P, Lymp J. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology. 2005;41:64–71. - PubMed
LinkOut - more resources
Full Text Sources
Medical